ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2024
Invasive group A streptococcal disease surveillance in Canada, 2021-2022.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Performance of the Xpert Xpress Strep A for detection ofMicrobiology spectrum · 2026Article
- Dynamics of public health messaging and healthcare activity in children during the 2022 iGAS surge: an observational study in England.Journal of public health (Oxford, England) · 2026Observational
- Invasive Group A Streptococcal Disease in Persons Experiencing Postpandemic Homelessness in Canada.JAMA network open · 2026Article
- Invasive Group A Streptococcal Infection in Children, 1992-2023.JAMA network open · 2025Article
- Comparison of pharyngeal and invasive isolates ofMicrobiology spectrum · 2025Article
- Molecular and Clinical Characterization of InvasivePathogens (Basel, Switzerland) · 2025Article
- A century of weekly notifiable disease incidence data by province in Canada.PLOS global public health · 2025Article
- Group A streptococcal infections in Alberta, Canada 2018-2023.Epidemiology and infection · 2024Article
- Group A Streptococcus Infections in Children: Epidemiological Insights Before and After the COVID-19 Pandemic.Pathogens (Basel, Switzerland) · 2024Review
- Invasive Group A Streptococcus Hypervirulent M1Emerging infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Invasive group A streptococcal (iGAS, Methods: The Public Health Agency of Canada's National Microbiology Laboratory collaborates with provincial and territorial public health laboratories to conduct national surveillance of invasive Results: Overall, the incidence of iGAS disease in Canada was 5.56 cases per 100,000 population in 2021, decreasing from the peak of 8.6 cases per 100,000 population in 2018. A total of 2,630 iGAS isolates were collected during 2022, representing an increase from 2021 (n=2,179). In particular, there was a large increase in isolates collected from October to December 2022. The most predominant Conclusion: The increase of iGAS isolates collected in Canada is an important public health concern. Continued surveillance of iGAS is critical to monitor expanding
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.